Abstract
Background
Although lobectomy is a viable alternative to total thyroidectomy (TT) in low-risk 1 to 4 cm papillary thyroid carcinoma (PTC), lobectomy is associated with higher locoregional recurrence risk and need for completion TT upon discovery of a previously unrecognized histologic high-risk feature (HRF). The present study evaluated long-term cost-effectiveness between lobectomy and TT.
Methods
Our base case was a hypothetical female cohort aged 40 years with a low-risk 2.5 cm PTC. A Markov decision tree model was constructed to compare cost-effectiveness between lobectomy and TT after 25 years. Patients with an unrecognized HRF (including aggressive histology, microscopic extrathyroidal extension, lymphovascular invasion, positive resection margin, nodal metastasis >5 mm, and multifocality) underwent completion TT after lobectomy. Outcome probabilities, utilities, and costs were estimated from the literature. The threshold for cost-effectiveness was set at US$50,000/quality-adjusted life-year (QALY). Sensitivity and threshold analyses were used to examine model uncertainty.
Results
After 25 years, each patient who underwent lobectomy instead of TT cost an extra US$772.08 but gained an additional 0.300 QALY. The incremental cost-effectiveness ratio was US$2577.65/QALY. In the sensitivity analysis, the lobectomy arm began to become cost-effective only after 3 years. Despite varying the reported prevalence of clinically unrecognized HRFs, complication from surgical procedures, annualized recurrence rates, unit cost of surgical procedure or complication, and utility score, lobectomy remained more cost-effective than TT.
Conclusions
Despite the higher locoregional recurrence risk and having almost half of the patients undergoing completion TT after lobectomy upon discovery of a previously unrecognized HRF, initial lobectomy was a more cost-effective long-term option than initial TT for 1 to 4 cm PTCs without clinically recognized HRFs.
Similar content being viewed by others
References
Cancer Incidence and Mortality in Hong Kong, 1983–2013. Hong Kong cancer registry. http://www3.ha.org.hk/cancereg/e_stat.asp. Accessed 15 Jan 2016.
Lang BH, Wong CK, Yu HW, Lee KE. Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma. Head Neck. 2016;38(S1):E1256–63.
Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
National Cancer Comprehensive Network (NCCN). Thyroid carcinoma guidelines. Version 2. 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 16 Jan 2016.
Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(suppl 1):1–122.
Kluijfhout WP, Pasternak JD, Lim J, et al. Frequency of high-risk characteristics requiring total thyroidectomy for 1- to 4-cm well-differentiated thyroid cancer. Thyroid. In press.
Lang BH, Shek TW, Wan KY. The significance of unrecognized histologic high-risk features on response-to-therapy in papillary thyroid carcinoma measuring 1–4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf). In press.
Rosario PW, Mourão GF, Calsolari MR. Apparently intrathyroid papillary thyroid carcinoma >1 cm and ≤4 cm: is the need for completion thyroidectomy common among patients submitted to lobectomy? Clin Endocrinol (Oxf). In press.
Pisanu A, Porceddu G, Podda M, Cois A, Uccheddu A. Systematic review with meta-analysis of studies comparing intraoperative neuromonitoring of recurrent laryngeal nerves versus visualization alone during thyroidectomy. J Surg Res. 2014;188:152–61.
Jeannon JP, Orabi AA, Bruch GA, Abdalsalam HA, Simo R. Diagnosis of recurrent laryngeal nerve palsy after thyroidectomy: a systematic review. Int J Clin Pract. 2009;63(4):624-9
Chadwick D, Kinsman R. The British Association of endocrine and thyroid surgeons—Fourth National Audit Report. Henley-on-Thames, UK: Dendrite Clinical Systems Ltd; 2012. http:www.baets.org.ukwp-contentuploads14th-ational-Audit.pdf. Accessed 26 April 2016
Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg. 2008;393(5):667-673.
Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM. Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. J Clin Endocrinol Metab. 2012;97:2243–55.
Kupferman ME, Patterson DM, Mandel SJ, LiVolsi V, Weber RS. Safety of modified radical neck dissection for differentiated thyroid carcinoma. Laryngoscope. 2004;114:403–6.
Welch K, McHenry CR. Selective lateral compartment neck dissection for thyroid cancer. J Surg Res. 2013;184:193–9.
Roh JL, Kim DH, Park CI. Prospective identification of chyle leakage in patients undergoing lateral neck dissection for metastatic thyroid cancer. Ann Surg Oncol. 2008;15:424–9.
Mekel M, Stephen AE, Gaz RD, et al. Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer. Am J Surg. 2010;199:485–90.
Glenn JA, Yen TW, Fareau GG, Carr AA, Evans DB, Wang TS. Institutional experience with lateral neck dissections for thyroid cancer. Surgery. 2015;158:972–8
Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–81.
Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68–79.
Lee J, Park JH, Lee CR, Chung WY, Park CS. Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid. 2013;23:1408–15.
Wang TS, Cheung K, Mehta P, Roman SA, Walker HD, Sosa JA. To stimulate or withdraw? A cost–utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. J Clin Endocrinol Metab. 2010;95:1672–80.
Kebebew E, Duh QY, Clark OH. Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World J Surg. 2000;24:1295–302.
Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File, 1999–2014, on CDC WONDER Online Database, released December 2015. Available at http://wonder.cdc.gov/cmf-icd10.html. Accessed 25 Feb 2016.
Overview of the Medicare physician fee schedule search. 2016. https://www.cms.gov/apps/physician-fee-schedule/overview.aspx. Accessed February 25, 2016.
MEDPAR Medicare fee for service for Parts A and B. 2016. Available at http://www.cms.gov/MedicareFeeforSvcPartsAB/03_MEDPAR.asp#TopOfPage. Accessed February 25, 2016.
HCUPnet. A tool for identifying, tracking, and analyzing national hospital statistics. 2016. Available at: http://hcupnet.ahrq.gov/. Accessed February 25, 2016.
Shrime MG, Goldstein DP, Seaberg RM, Rotstein L, Freeman JL, Gullane PJ. Cost-effective management of low-risk papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:1245–53.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–58
Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–5.
Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645–9.
Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–61.
Lee CR, Son H, Lee S, et al. Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy? World J Surg. 2014;38:872–7.
Disclosure
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lang, B.HH., Wong, C.K.H. Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features. Ann Surg Oncol 23, 3641–3652 (2016). https://doi.org/10.1245/s10434-016-5280-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5280-6